Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.

The treatment temporarily improved symptoms of hyperandrogenism in adolescents.

New steroid derivatives show promise as anticancer agents, even against resistant cells.

5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Eplerenone, a mineralocorticoid receptor antagonist, was found to promote hair growth in human hair follicles.

Oral spironolactone and isotretinoin are effective for treating acne.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.

UVB exposure affects retinoid metabolism, which is important for skin cancer progression and treatment.

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

Androsterone and finasteride have different solid forms, with new findings correcting previous errors and identifying a new form.

5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.

Finasteride can cause rare but serious skin rashes.

The rs1128977 gene variant may affect cholesterol and body measurements.

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

Castration and finasteride lower urinary oxalate in male rats, potentially treating urolithiasis.

Some oral medications may help treat central serous chorioretinopathy, especially eplerenone, but more research is needed.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.